Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells.
about
Review: Application of Nanoparticles in Urothelial Cancer of the Urinary BladderIntratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer modelVirotherapy clinical trials for regional disease: in situ immune modulation using recombinant poxvirus vectors.Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies.Local and systemic response of mice to interferon-alpha 1-transfected Friend leukemia cells.Therapy of murine mammary carcinoma metastasis with interferon gamma and MHC gene-transduced tumour cells.Molecular characterization of defective antigen processing in human prostate cancer.Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing miceHerpes simplex virus (HSV)-mediated ICAM-1 gene transfer abrogates tumorigenicity and induces anti-tumor immunity.Interleukin-2 gene transfer into human transitional cell carcinoma of the urinary bladder.Immunotherapy in ovarian cancer.Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen.Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system.Targeting epigenetic mechanisms for clinical translation: enhancing the efficacy of tumor immunotherapies.Adenovirus-mediated suicide-gene therapy in an orthotopic murine bladder tumor model.Antigenic Differences Between Normal and Malignant Cells as a Basis for Treatment of Intracerebral Neoplasms Using a DNA-Based Vaccine.RNA interference-mediated silencing of Foxo3 in antigen-presenting cells as a strategy for the enhancement of DNA vaccine potency.A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging.Considerations for the use of cytokine-secreting tumor cell preparations for cancer treatment.Neoadjuvant treatment of hepatic malignancy: an oncolytic herpes simplex virus expressing IL-12 effectively treats the parent tumor and protects against recurrence-after resection.An optimum anti-melanoma response in mice immunized with fibroblasts transfected with DNA from mouse melanoma cells requires the expression of both syngeneic and allogeneic MHC-determinants.The potential applications of gene transfer in the treatment of patients with cancer: a concise review.Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing.Locoregional IL-2 immunotherapy of bladder cancer.Current status of gene therapy for prostate and bladder cancer.Breast cancer: cell and gene therapy.Retrovirus-mediated transfer of prothymosin gene inhibits tumor growth and prolongs survival in murine bladder cancer.Cytokine gene modification of bladder cancer cells for the establishment of bladder cancer vaccine.Gene Therapy of Bladder Cancer.Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model.A Phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: monitoring the humoral immune response.Rejection of mouse renal cell carcinoma elicited by local secretion of interleukin-2.Antitumor effects of interleukin-2 gene-modified fibroblasts in an orthotopic colon cancer model.Influence of CD4 T cells and the source of major histocompatibility complex class II-restricted peptides on cytotoxic T-cell priming by dendritic cellsWhole-tissue biopsy phenotyping of three-dimensional tumours reveals patterns of cancer heterogeneity
P2860
Q28386921-CE323D70-E7DC-4783-990B-A5D9D163946DQ33989165-F6C16E2A-D49B-4435-92FD-C5E814F23725Q34169782-2176072A-3912-439F-9985-5DB2A149AD1AQ35088311-3EED1E71-CA8B-4013-A9C7-46A2EEBF0029Q35796105-76595C27-BC41-4BBB-8503-49B3E8C6424FQ36136494-BE9AC98E-BCD1-4818-BAD8-B0D7C546021AQ36183805-E5324B1B-ACE3-485A-BC3C-D963ED7BBCDBQ36364365-1E54C683-F337-4BDB-9025-09A7436FDF41Q36438502-405A44BF-5DE9-4FFF-A86E-664D9BE4B651Q36618832-0ABD4E4E-56AF-4EBE-8433-02E2C17F7B69Q36631249-3CE8E301-CDB4-4F1F-9BA3-A194854BAD6EQ36914397-32AF9568-F577-4FDB-926E-CD8CF2F8BE9BQ37340361-B72E326F-E39B-4CB1-A7F9-80BA0E82D2C9Q38159805-C4CFA6F0-B779-4D3D-AC5A-0FFA72AF8309Q38522626-3AE3F0E4-71C1-4061-BDE3-DA60F2719BEAQ39445959-66633566-5F43-4E4A-B5B2-1A48A70F64A1Q39627674-61FEF1CE-576F-469F-807A-93B33F666F14Q40082035-BC4CF93D-6A45-4A75-B546-6A7CEC63115FQ40603524-A33EE011-5B3E-46BF-8B61-C9BE02219E21Q40663869-19EF99B2-427C-44DB-A712-4B1C0C9D8A3AQ40711676-2614E120-C6CC-475C-B960-19E48ABD0A12Q41020855-DF4AA998-7A32-480E-809D-BD78B014AF4DQ41354177-89002BB3-ED90-4490-A33B-7B3B7CE92396Q41362909-95136AE0-5DFF-468E-9B7E-79887D0C8FF1Q41631041-E51F423A-5736-40A6-B5EA-B4A6BCDA9F60Q41669404-111640F1-1C79-4B43-903E-550F7C6D75CAQ43544045-916C2B34-8B30-4960-AFF8-79F0A356079AQ45858694-BA630CA3-1F03-420A-81F9-096E6AD8A8DDQ45866737-2A28086C-2C0D-4ED2-9558-E93B8C65680DQ45868408-A334803D-BFF3-4C4B-97D9-F508949487F0Q45882929-C2D4CC2F-139B-4051-866E-492AF8ECD668Q52047487-854D1EBC-A4CE-49D3-8F46-575CB31B0B61Q55517731-22073D75-BEB6-4FA7-B09E-275F5320A269Q56967605-028B47D8-79CC-4E08-A074-4B17C825D824Q57971162-5AEBCB7C-3FD6-4B85-AB15-99EE0BD4B229
P2860
Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Regression of bladder tumors i ...... n 2 gene-modified tumor cells.
@en
type
label
Regression of bladder tumors i ...... n 2 gene-modified tumor cells.
@en
prefLabel
Regression of bladder tumors i ...... n 2 gene-modified tumor cells.
@en
P2093
P2860
P356
P1476
Regression of bladder tumors i ...... n 2 gene-modified tumor cells.
@en
P2093
P2860
P304
P356
10.1084/JEM.177.4.1127
P407
P577
1993-04-01T00:00:00Z